Study on anti-depression effect of Suanzaoren Decoction based on liver metabolomics.
10.19540/j.cnki.cjcmm.20240902.703
- Author:
Jing LI
1
;
Ya-Nan TONG
2
;
Hong-Tao WANG
2
;
Shao-Hua ZHAO
2
;
Wei-Yan CHEN
3
;
Zhi-Wei LI
4
;
Min-Yan LIU
5
Author Information
1. Shijiazhuang University, Heibei Tibetan Medicine Quality and Technology Innovation Center Shijiazhuang 050035, China Hebei University of Science and Technology Shijiazhuang 050018, China.
2. Shijiazhuang Yiling Pharmaceutical Co., Ltd. Shijiazhuang 050035, China.
3. the Second Hospital of Hebei Medical University Shijiazhuang 050000, China.
4. Hebei University of Science and Technology Shijiazhuang 050018, China.
5. Shijiazhuang University, Heibei Tibetan Medicine Quality and Technology Innovation Center Shijiazhuang 050035, China.
- Publication Type:Journal Article
- Keywords:
Suanzaoren Decoction;
UPLC-Q-TOF-MS;
action mechanism;
depression induced by chronic unpredictable mild stress;
liver metabolomics;
metabolic pathway
- MeSH:
Animals;
Rats;
Drugs, Chinese Herbal/administration & dosage*;
Metabolomics;
Depression/metabolism*;
Male;
Liver/drug effects*;
Rats, Sprague-Dawley;
Antidepressive Agents/administration & dosage*;
Serotonin/blood*;
Humans;
Disease Models, Animal;
Behavior, Animal/drug effects*
- From:
China Journal of Chinese Materia Medica
2025;50(1):19-31
- CountryChina
- Language:Chinese
-
Abstract:
To explore the anti-depression effect of Suanzaoren Decoction(SZRD), the regulatory effects on endogenous metabolites in the liver of rats with depression induced by chronic unpredictable mild stress(CUMS) were analyzed by using LC-MS metabolomics. The rats were randomly divided into normal control group, model group, low-dose SZRD group, high-dose SZRD group, and positive drug group. The CUMS depression model was replicated by applying a variety of stimuli, such as fasting and water deprivation, ice water swimming, hot water swimming, day and night reversal, tail clamping, and restraint for rats. Modeling and treatment were conducted for 56 days. The behavioral indexes of rats in each group, including body weight, open field test, sucrose preference test, and tail suspension test, were observed. Plasma samples and liver tissue samples were collected, and the contents of 5-hydroxytryptamine(5-HT), dopamine(DA), and norepinephrine(NE) in plasma were measured using enzyme-linked immunosorbent assay(ELISA). Meanwhile, the regulatory effects of SZRD on the liver metabolic profile of CUMS model rats were analyzed by the LC-MS metabolomics method. The results show that SZRD can significantly improve the depression-like behavior of CUMS model rats and increase the neurotransmitter levels of 5-HT, DA, and NE in plasma. A total of 24 different metabolites in the rats' liver are identified using the LC-MS metabolomics method, and SZRD can reverse 13 of these metabolites. Metabolic pathway analysis indicates that nine metabolic pathways are found to be significantly associated with depression, and in the low-dose SZRD group, four pathways can be regulated, including pentose phosphate pathway, purine metabolism, inositol phosphate metabolism, and sphingolipid metabolism. In the high-dose SZRD group, two metabolic pathways can be regulated, including sphingolipid metabolism and glycerol glycerophospholipid metabolism. Sphingolipid metabolism is a metabolic pathway that can be regulated by SZRD at different doses, so it is speculated that it may be the primary pathway through which SZRD can alleviate metabolic disturbances in the liver of CUMS model rats.
